Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Breast Cancer Stage II Clinical Trial

Official title:

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05877859
• Other study ID #: STUDY00005452
• Secondary ID: NCI-2023-02943ST
• Status: Recruiting
• Start date: May 30, 2023
• Est. completion date: April 10, 2026

Study information

• Verified date: May 2024
• Source: Emory University
• Contact: Ruth Sacks, MD
• Phone: 404-778-1900
• Email: rlsacks[@]emory.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.

Description:

Primary Objective:

I. To determine whether standard of care neoadjuvant chemo-immunotherapy leads to the induction of a pro-inflammatory cytokine milieu (characterized by high IFN- γ, IFN-α, IL-6 and low TGF-β) in the blood which is induced within 24 hours of treatment initiation, persists through the course of the therapy and is associated with pathologic complete response in the tissue.

Secondary Objectives:

I. To determine whether the spatially resolved tissue TGF-β induced transcriptomic signatures or lack of innate interferon inducible genes/effector CD8 modules are abundant in tumors from TNBC patients that do not show pathologic complete response in the tissue at the end of standard of care neoadjuvant chemo- immunotherapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: April 10, 2026
• Est. primary completion date: April 10, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Newly diagnosed, previously untreated, non-metastatic Stage II-III invasive breast cancer

• Estrogen receptor IHC expression =10%; progesterone receptor IHC expression = 10%; HER2 negative

• HER2 negativity is defined as either of the following by local laboratory assessment:

• IHC 0, 1+, or 2+ and In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 <2.0 or single probe average HER2 gene copy number <4 signals/cell)

• No prior chemotherapy, endocrine therapy, or immunotherapy

• Willingness and ability of the subject to comply with scheduled visits, standard of care drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.

• Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

• Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study

• Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of first dose of study drugs.

• Patients on steroid medications (i.e. prednisone, dexamethasone, etc.) that are not part of the standard pre-medications and/or take home medications that are included as a part of medication regimen for the pre-operative chemo-immunotherapy described in the study.

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in this study.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study agents. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Related Conditions & MeSH terms

• Breast Cancer Invasive
• Breast Cancer Stage II
• Breast Cancer Stage III
• Breast Cancer Triple Negative
• Breast Neoplasms
• Triple Negative Breast Neoplasms

Locations

Country	Name	City	State
United States	Emory University/Winship Cancer Institute	Atlanta	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the cytokine milieu in the blood	The change in the cytokine milieu specifically IFN-?, IFN-a, IL-6 and TGF-ß in the blood during standard of care neoadjuvant chemo-immunotherapy and its association with pathologic complete response in the tissue	From baseline within 24 hours of surgery
Secondary	Change in the transcriptomic signatures in the tissue	The transcriptomic signatures of TGF-ß induced genes and innate interferon inducible genes/effector CD8 in the tissue specimens collected at baseline (archival tissue obtained prior to standard of care neoadjuvant chemo- immunotherapy) and after completion of treatment at the time of surgery.	From baseline within 24 hours of surgery